PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX • US6951271005

22.2 USD
+0.75 (+3.5%)
Last: Feb 13, 2026, 01:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX has a bad growth rate and is valued cheaply. These ratings could make PCRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • PCRX had positive earnings in the past year.
  • In the past year PCRX had a positive cash flow from operations.
  • Of the past 5 years PCRX 4 years were profitable.
  • PCRX had a positive operating cash flow in each of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • PCRX's Return On Assets of 1.65% is amongst the best of the industry. PCRX outperforms 81.15% of its industry peers.
  • PCRX has a better Return On Equity (2.95%) than 82.20% of its industry peers.
  • PCRX has a better Return On Invested Capital (3.63%) than 81.68% of its industry peers.
  • PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.66%.
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROIC 3.63%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.99%, PCRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 8.88%, PCRX belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
  • PCRX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 84.29% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • PCRX has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PCRX has been increased compared to 5 years ago.
  • The debt/assets ratio for PCRX is higher compared to a year ago.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 1.89 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PCRX has a Altman-Z score of 1.89. This is comparable to the rest of the industry: PCRX outperforms 59.69% of its industry peers.
  • The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.03, PCRX belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
  • PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 62.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Altman-Z 1.89
ROIC/WACC0.46
WACC7.93%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
  • PCRX has a Current ratio of 5.26. This is in the better half of the industry: PCRX outperforms 64.40% of its industry peers.
  • A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
  • PCRX has a Quick ratio (3.78) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 3.78
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for PCRX have decreased by -6.90% in the last year.
  • PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
  • PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%

3.2 Future

  • Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 7.01% on average per year.
  • The Revenue is expected to grow by 6.38% on average over the next years.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 7.47, which indicates a rather cheap valuation of PCRX.
  • 93.72% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.67, PCRX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 6.39, the valuation of PCRX can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 94.24% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.69, PCRX is valued rather cheaply.
Industry RankSector Rank
PE 7.47
Fwd PE 6.39
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, PCRX is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.69
EV/EBITDA 6.18
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.54
EPS Next 2Y4.05%
EPS Next 3Y6.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/13/2026, 1:43:09 PM)

22.2

+0.75 (+3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners114.44%
Inst Owner Change-1.64%
Ins Owners0.79%
Ins Owner Change-6.78%
Market Cap955.04M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (36.53%)
Short Float %16.85%
Short Ratio7.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-20.55%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE 7.47
Fwd PE 6.39
P/S 1.33
P/FCF 7.69
P/OCF 6.75
P/B 1.31
P/tB 2.94
EV/EBITDA 6.18
EPS(TTM)2.97
EY13.38%
EPS(NY)3.48
Fwd EY15.66%
FCF(TTM)2.89
FCFY13.01%
OCF(TTM)3.29
OCFY14.81%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.54
Graham Number33.61
Profitability
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROCE 5.34%
ROIC 3.63%
ROICexc 4.58%
ROICexgc 7.99%
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
FCFM 17.33%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Debt/EBITDA 2.44
Cap/Depr 18.95%
Cap/Sales 2.4%
Interest Coverage 4.07
Cash Conversion 91.52%
Profit Quality 579.36%
Current Ratio 5.26
Quick Ratio 3.78
Altman-Z 1.89
F-Score7
WACC7.93%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.


What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.47 and the Price/Book (PB) ratio is 1.31.